Novel obesity treatment company EnteroMedics (NASDAQ:ETRM) that has survived a close brush with disaster recorded revenue for the first time since it was incorporated nearly eight years ago. On Tuesday, the company reported revenue of about $123,000 in the first quarter of the year that were garnered from the sale of its implantable neuromodulation system — Maestro […]
Obese Australians will be among the first in the world to use a Minnesota company’s therapy that uses an implantable neurostimulator to achieve weight loss. EnteroMedics (NASDAQ:ETRM) announced this week that it has shipped its first commercially available Maestro Rechargeable System to its distribution partner in Australia. The Maestro system delivers VBLOC (vagus nerve-blocking therapy) designed to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
EnteroMedics Inc. (NASDAQ:ETRM) closed its $29.8 million public offering of 17 million shares of common stock and 17 million corresponding warrants. The St. Paul, Minnesota-based anti-obesity device maker plans to use the $27.6 million it netted from the offering to support the regulatory approval of its neuroblocking Maestro RC system. The stock went for aggregate […]
Ernie Andberg has a little more free time on his hands these days. The long-time “emerging medical device companies” equity analyst for Feltl & Co. in Minneapolis has not seen a lot of companies emerging lately. In fact, they’ve been disappearing all together. Case in point: Medtronic Inc.’s (NYSE: MDT) deal last week to acquire […]